In addition, our data also showed that EGFR, HER3 and HER4 genes were more likely to be amplified in the patients with early-stage tumors, suggesting that these aberrations may be early-stage genetic events, contributing to tumor initiation and tumorigenesis. This evidence concerns the gene EGFR and neoplasm.